Chronic pain affects more than 50 million Americans, yet for decades, treatment options for pain that persists in the absence ...

Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with benefits also continuing well after treatment has stopped.

Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with ...

Topline data were announced from a phase 3b trial evaluating the concomitant use of ixekizumab and tirzepatide in active PsA and obesity.

India, Jan. 12 -- Arthritis is a broad term that covers conditions in which joints become inflamed, painful, and often less ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial ...

In a phase IIIb trial of adults with active psoriatic arthritis (PsA) and obesity or overweight, adding the GLP-1 drug ...

Both upadacitinib (Rinvoq) and adalimumab (Humira) are proven effective in rheumatoid arthritis (RA) and psoriatic arthritis ...

Eli Lilly said Thursday that adding its weight loss drug Zepbound on top of its immunology therapy Taltz helped obese ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the novel TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound ...

Add Yahoo as a preferred source to see more of our stories on Google. Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake Jan ...

Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis ...